NEW YORK – Qiagen said on Thursday that its first quarter revenues and earnings per share are expected to be significantly higher than previously issued guidance, primarily due to sales of products used in COVID-19 testing.
For the three months ended March 31, 2020, Qiagen reported preliminary revenue growth of 9 percent at constant exchange rates, compared to a prior outlook, issued on Feb. 4, of approximately 2 percent to 3 percent growth.
Sales reflected "very significant" demand for products used in COVID-19 testing against weaker customer demand in other product areas.